{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:21:03Z","timestamp":1793370063165,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T00:00:00Z","timestamp":1735948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Dental and Craniofacial Research Intramural Research Program"},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by hypersecretion of fibroblast growth factor 23 (FGF23) by typically benign phosphaturic mesenchymal tumors (PMTs). FGF23 excess causes chronic hypophosphatemia through renal phosphate losses and decreased production of 1,25-dihydroxy-vitamin-D. TIO presents with symptoms of chronic hypophosphatemia including fatigue, bone pain, weakness, and fractures. Definitive treatment is surgical resection of the PMT with wide margins. Other therapeutic options are necessary when the tumor is unable to be localized, not amenable to complete resection, or when the patient is not a good surgical candidate. Alternative ablative approaches such as radiotherapy, radiofrequency ablation, and cryoablation, have been used with variable success and limited follow up. Medical management is warranted both prior to definitive therapy and in non-operable cases to improve symptoms and allow for bone remineralization. Oral phosphate and calcitriol were the mainstay of medical therapy, however, the development of burosumab, a monoclonal blocking antibody to FGF23, has introduced an approved therapy that improves hypophosphatemia and symptoms in patients with TIO. In select cases, cinacalcet can be an effective adjuvant to phosphate and calcitriol. Continued monitoring for tumor growth is necessary while on medical therapy. Infigratinib, a selective FGFR tyrosine-kinase inhibitor targeting a causative tumoral fusion protein, can reverse the biochemical findings of TIO and possibly reduce tumor mass; however, its use is constrained by serious side effects. Overall, innovations in medical and interventional treatments have broadened therapeutic options for patients with PMTs, particularly in cases where a curative surgical resection is not possible.<\/jats:p>","DOI":"10.1007\/s00223-024-01317-x","type":"journal-article","created":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T17:18:16Z","timestamp":1736011096000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment Advances in Tumor-Induced Osteomalacia"],"prefix":"10.1007","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1029-3284","authenticated-orcid":false,"given":"Iris R.","family":"Hartley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0284-5299","authenticated-orcid":false,"given":"Kelly L.","family":"Roszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,4]]},"reference":[{"issue":"1","key":"1317_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","volume":"28","author":"AL Folpe","year":"2004","unstructured":"Folpe AL et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28(1):1\u201330","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"1317_CR2","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jbmr.1881","volume":"28","author":"WH Chong","year":"2013","unstructured":"Chong WH et al (2013) Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res 28(6):1386\u20131398","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1317_CR3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00223-020-00691-6","volume":"108","author":"P Florenzano","year":"2021","unstructured":"Florenzano P et al (2021) Tumor-induced osteomalacia. Calcif Tissue Int 108(1):128\u2013142","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"1317_CR4","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1002\/jps.22614","volume":"100","author":"K Miyamoto","year":"2011","unstructured":"Miyamoto K et al (2011) Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. J Pharm Sci 100(9):3719\u20133730","journal-title":"J Pharm Sci"},{"issue":"3","key":"1317_CR5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T et al (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19(3):429\u2013435","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1317_CR6","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1530\/ERC-11-0006","volume":"18","author":"WH Chong","year":"2011","unstructured":"Chong WH et al (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18(3):R53-77","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"1317_CR7","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/jbmr.4702","volume":"37","author":"IR Hartley","year":"2022","unstructured":"Hartley IR et al (2022) Determination of FGF23 levels for the diagnosis of FGF23-mediated hypophosphatemia. J Bone Miner Res 37(11):2174\u20132185","journal-title":"J Bone Miner Res"},{"key":"1317_CR8","first-page":"90","volume":"7","author":"P Florenzano","year":"2017","unstructured":"Florenzano P, Gafni RI, Collins MT (2017) Tumor-induced osteomalacia Bone Rep 7:90\u201397","journal-title":"Tumor-induced osteomalacia Bone Rep"},{"issue":"10","key":"1317_CR9","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","volume":"294","author":"SM Jan de Beur","year":"2005","unstructured":"Jan de Beur SM (2005) Tumor-induced osteomalacia. JAMA 294(10):1260\u20131267","journal-title":"JAMA"},{"issue":"1\u20132","key":"1317_CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/2042018816678363","volume":"8","author":"RH Bishay","year":"2017","unstructured":"Bishay RH, Ganda K, Seibel MJ (2017) Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature. Ther Adv Endocrinol Metab 8(1\u20132):14\u201319","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"4","key":"1317_CR11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2967\/jnmt.116.177873","volume":"44","author":"S Basu","year":"2016","unstructured":"Basu S, Fargose P (2016) 177Lu-DOTATATE PRRT in recurrent skull-base phosphaturic mesenchymal tumor causing osteomalacia: a potential application of PRRT beyond neuroendocrine tumors. J Nucl Med Technol 44(4):248\u2013250","journal-title":"J Nucl Med Technol"},{"issue":"5","key":"1317_CR12","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","volume":"112","author":"M Riminucci","year":"2003","unstructured":"Riminucci M et al (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112(5):683\u2013692","journal-title":"J Clin Invest"},{"issue":"2","key":"1317_CR13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/ddt429","volume":"23","author":"YH Lim","year":"2014","unstructured":"Lim YH et al (2014) Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet 23(2):397\u2013407","journal-title":"Hum Mol Genet"},{"issue":"5","key":"1317_CR14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00000441-199105000-00006","volume":"301","author":"K Konishi","year":"1991","unstructured":"Konishi K et al (1991) Hypophosphatemic osteomalacia in von Recklinghausen neurofibromatosis. Am J Med Sci 301(5):322\u2013328","journal-title":"Am J Med Sci"},{"issue":"4925","key":"1317_CR15","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/bmj.1.4925.1311","volume":"1","author":"PD Saville","year":"1955","unstructured":"Saville PD et al (1955) Osteomalacia in Von Recklinghausen\u2019s neurofibromatosis; metabolic study of a case. Br Med J 1(4925):1311\u20131313","journal-title":"Br Med J"},{"issue":"3","key":"1317_CR16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/joim.13593","volume":"293","author":"SM Jan de Beur","year":"2023","unstructured":"Jan de Beur SM et al (2023) Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. J Intern Med 293(3):309\u2013328","journal-title":"J Intern Med"},{"key":"1317_CR17","doi-asserted-by":"crossref","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","volume":"3","author":"S Minisola","year":"2017","unstructured":"Minisola S et al (2017) Tumour-induced osteomalacia. Nat Rev Dis Primers 3:17044","journal-title":"Nat Rev Dis Primers"},{"key":"1317_CR18","doi-asserted-by":"crossref","first-page":"101979","DOI":"10.1016\/j.foot.2023.101979","volume":"55","author":"A Strydom","year":"2023","unstructured":"Strydom A et al (2023) Tumor induced osteomalacia from a peripheral mesenchymal tumour of the foot. Foot (Edinb) 55:101979","journal-title":"Foot (Edinb)"},{"issue":"3","key":"1317_CR19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00774-016-0756-9","volume":"35","author":"WJ Yu","year":"2017","unstructured":"Yu WJ et al (2017) Reports of 17 Chinese patients with tumor-induced osteomalacia. J Bone Miner Metab 35(3):298\u2013307","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"1317_CR20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00223-022-01005-8","volume":"111","author":"A Bosman","year":"2022","unstructured":"Bosman A et al (2022) Tumor-induced osteomalacia: a systematic clinical review of 895 cases. Calcif Tissue Int 111(4):367\u2013379","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"1317_CR21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s13193-021-01449-8","volume":"13","author":"K Thakur","year":"2022","unstructured":"Thakur K et al (2022) Metastatic malignant phosphaturic mesenchymal tumor of mandibular alveolus: a rare case report and review of literature. Indian J Surg Oncol 13(2):305\u2013311","journal-title":"Indian J Surg Oncol"},{"issue":"3","key":"1317_CR22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12105-015-0678-1","volume":"10","author":"JK Wasserman","year":"2016","unstructured":"Wasserman JK et al (2016) Phosphaturic mesenchymal tumor involving the head and neck: a report of five cases with FGFR1 fluorescence in situ hybridization analysis. Head Neck Pathol 10(3):279\u2013285","journal-title":"Head Neck Pathol"},{"issue":"10","key":"1317_CR23","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/PAS.0000000000000890","volume":"41","author":"A Agaimy","year":"2017","unstructured":"Agaimy A et al (2017) Phosphaturic mesenchymal tumors: clinicopathologic, immunohistochemical and molecular analysis of 22 cases expanding their morphologic and immunophenotypic spectrum. Am J Surg Pathol 41(10):1371\u20131380","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"1317_CR24","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s11547-021-01412-1","volume":"126","author":"MAM Hussein","year":"2021","unstructured":"Hussein MAM et al (2021) Phosphaturic mesenchymal tumors: radiological aspects and suggested imaging pathway. Radiol Med 126(12):1609\u20131618","journal-title":"Radiol Med"},{"issue":"9308","key":"1317_CR25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","volume":"359","author":"SM Jan de Beur","year":"2002","unstructured":"Jan de Beur SM et al (2002) Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359(9308):761\u2013763","journal-title":"Lancet"},{"key":"1317_CR26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2014.04.016","volume":"64","author":"S Breer","year":"2014","unstructured":"Breer S et al (2014) 68Ga DOTA-TATE PET\/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT\/CT. Bone 64:222\u2013227","journal-title":"Bone"},{"issue":"2","key":"1317_CR27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/jc.2012-3642","volume":"98","author":"RJ Clifton-Bligh","year":"2013","unstructured":"Clifton-Bligh RJ et al (2013) Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET\/CT. J Clin Endocrinol Metab 98(2):687\u2013694","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1317_CR28","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1210\/jc.2016-2052","volume":"101","author":"D El-Maouche","year":"2016","unstructured":"El-Maouche D et al (2016) (68)Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab 101(10):3575\u20133581","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1317_CR29","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jbmr.316","volume":"26","author":"P Andreopoulou","year":"2011","unstructured":"Andreopoulou P et al (2011) Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res 26(6):1295\u20131302","journal-title":"J Bone Miner Res"},{"key":"1317_CR30","doi-asserted-by":"crossref","first-page":"116077","DOI":"10.1016\/j.bone.2021.116077","volume":"152","author":"C Crotti","year":"2021","unstructured":"Crotti C et al (2021) Tumor induced osteomalacia: a single center experience on 17 patients. Bone 152:116077","journal-title":"Bone"},{"issue":"11","key":"1317_CR31","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1097\/CM9.0000000000001448","volume":"134","author":"Y Jiang","year":"2021","unstructured":"Jiang Y et al (2021) Consensus on clinical management of tumor-induced osteomalacia. Chin Med J (Engl) 134(11):1264\u20131266","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"1317_CR32","doi-asserted-by":"crossref","first-page":"bvab099","DOI":"10.1210\/jendso\/bvab099","volume":"5","author":"K Dahir","year":"2021","unstructured":"Dahir K et al (2021) Diagnosis and management of tumor-induced osteomalacia: perspectives from clinical experience. J Endocr Soc 5(9):bvab099","journal-title":"J Endocr Soc"},{"issue":"8","key":"1317_CR33","doi-asserted-by":"crossref","first-page":"e3428","DOI":"10.1210\/clinem\/dgac253","volume":"107","author":"D Rendina","year":"2022","unstructured":"Rendina D et al (2022) Tumor-induced osteomalacia: a systematic review and individual patient\u2019s data analysis. J Clin Endocrinol Metab 107(8):e3428\u2013e3436","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1317_CR34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/j.semdp.2019.07.002","volume":"36","author":"AL Folpe","year":"2019","unstructured":"Folpe AL (2019) Phosphaturic mesenchymal tumors: a review and update. Semin Diagn Pathol 36(4):260\u2013268","journal-title":"Semin Diagn Pathol"},{"issue":"3","key":"1317_CR35","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jbmr.3903","volume":"35","author":"X Li","year":"2020","unstructured":"Li X et al (2020) Nonremission and recurrent tumor-induced osteomalacia: a retrospective study. J Bone Miner Res 35(3):469\u2013477","journal-title":"J Bone Miner Res"},{"issue":"12","key":"1317_CR36","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/rheumatology\/39.12.1415","volume":"39","author":"GP Clunie","year":"2000","unstructured":"Clunie GP, Fox PE, Stamp TC (2000) Four cases of acquired hypophosphataemic (\u2018oncogenic\u2019) osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology (Oxford) 39(12):1415\u20131421","journal-title":"Rheumatology (Oxford)"},{"key":"1317_CR37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12891-015-0496-3","volume":"16","author":"ZJ Sun","year":"2015","unstructured":"Sun ZJ et al (2015) Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors. BMC Musculoskelet Disord 16:43","journal-title":"BMC Musculoskelet Disord"},{"issue":"9","key":"1317_CR38","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/jbmr.1642","volume":"27","author":"Y Jiang","year":"2012","unstructured":"Jiang Y et al (2012) Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature. J Bone Miner Res 27(9):1967\u20131975","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1317_CR39","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00198-020-05369-1","volume":"31","author":"L Colangelo","year":"2020","unstructured":"Colangelo L et al (2020) Long-term bone mineral density changes after surgical cure of patients with tumor-induced osteomalacia. Osteoporos Int 31(7):1383\u20131387","journal-title":"Osteoporos Int"},{"issue":"11","key":"1317_CR40","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1210\/clinem\/dgad252","volume":"108","author":"X Ni","year":"2023","unstructured":"Ni X et al (2023) Shift in calcium from peripheral bone to axial bone after tumor resection in patients with tumor-induced osteomalacia. J Clin Endocrinol Metab 108(11):e1365\u2013e1373","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1317_CR41","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1210\/jc.2013-2528","volume":"98","author":"VD Tarasova","year":"2013","unstructured":"Tarasova VD et al (2013) Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy. J Clin Endocrinol Metab 98(11):4267\u20134272","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1317_CR42","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10178","volume":"3","author":"SK Mishra","year":"2019","unstructured":"Mishra SK et al (2019) Successful management of tumor-induced osteomalacia with radiofrequency ablation: a case series. JBMR Plus 3(7):e10178","journal-title":"JBMR Plus"},{"issue":"9","key":"1317_CR43","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1210\/jc.2013-4515","volume":"99","author":"S Jadhav","year":"2014","unstructured":"Jadhav S et al (2014) Radiofrequency ablation, an effective modality of treatment in tumor-induced osteomalacia: a case series of three patients. J Clin Endocrinol Metab 99(9):3049\u20133054","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1317_CR44","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s00270-016-1350-1","volume":"39","author":"M Maybody","year":"2016","unstructured":"Maybody M et al (2016) Ga-68 DOTATOC PET\/CT-guided biopsy and cryoablation with autoradiography of biopsy specimen for treatment of tumor-induced osteomalacia. Cardiovasc Intervent Radiol 39(9):1352\u20131357","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"11","key":"1317_CR45","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/jbmr.3219","volume":"32","author":"SH Tella","year":"2017","unstructured":"Tella SH et al (2017) Multimodality image-guided cryoablation for inoperable tumor-induced osteomalacia. J Bone Miner Res 32(11):2248\u20132256","journal-title":"J Bone Miner Res"},{"key":"1317_CR46","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00256-024-04614-6","volume":"53","author":"MR Gonzalez","year":"2024","unstructured":"Gonzalez MR et al (2024) Phosphaturic mesenchymal tumor: management and outcomes of ten patients treated at a single institution. Skeletal Radiol 53:1495","journal-title":"Skeletal Radiol"},{"issue":"6","key":"1317_CR47","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/js.2016-1088","volume":"1","author":"A Nair","year":"2017","unstructured":"Nair A et al (2017) Peptide receptor radionuclide and octreotide: a novel approach for metastatic tumor-induced osteomalacia. J Endocr Soc 1(6):726\u2013730","journal-title":"J Endocr Soc"},{"issue":"3","key":"1317_CR48","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1159\/000510334","volume":"13","author":"S H\u00e4fliger","year":"2020","unstructured":"H\u00e4fliger S et al (2020) Peptide receptor radionuclide therapy for a phosphaturic mesenchymal tumor. Case Rep Oncol 13(3):1373\u20131380","journal-title":"Case Rep Oncol"},{"issue":"10","key":"1317_CR49","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1530\/EC-19-0341","volume":"8","author":"R Shah","year":"2019","unstructured":"Shah R et al (2019) Tumor induced osteomalacia in head and neck region: single center experience and systematic review. Endocr Connect 8(10):1330\u20131353","journal-title":"Endocr Connect"},{"key":"1317_CR50","unstructured":"Hartley IR, W.D., Hofman MS, Delahunt JW, Collins MT, Gafni RI (2019) Peptide receptor radionuclide therapy (PRRT) appears to be ineffective therapy for tumor-induced osteomalacia. American Society of Bone and Mineral Metabolism (ASBMR) Annual Meeting Book of Abstracts"},{"issue":"3","key":"1317_CR51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s12020-022-03039-2","volume":"76","author":"L Cianferotti","year":"2022","unstructured":"Cianferotti L et al (2022) Persistence and recurrence in tumor-induced osteomalacia: a systematic review of the literature and results from a national survey\/case series. Endocrine 76(3):709\u2013721","journal-title":"Endocrine"},{"issue":"4","key":"1317_CR52","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF03343720","volume":"23","author":"QL Huang","year":"2000","unstructured":"Huang QL, Feig DS, Blackstein ME (2000) Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. J Endocrinol Invest 23(4):263\u2013267","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1317_CR53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jbmr.4429","volume":"37","author":"D Ovejero","year":"2022","unstructured":"Ovejero D et al (2022) PTH and FGF23 exert interdependent effects on renal phosphate handling: evidence from patients with hypoparathyroidism and hyperphosphatemic familial tumoral calcinosis treated with synthetic human PTH 1\u201334. J Bone Miner Res 37(2):179\u2013184","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1317_CR54","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1359\/jbmr.070304","volume":"22","author":"JL Geller","year":"2007","unstructured":"Geller JL et al (2007) Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22(6):931\u2013937","journal-title":"J Bone Miner Res"},{"issue":"11","key":"1317_CR55","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1210\/jc.2013-2705","volume":"98","author":"SK Bhadada","year":"2013","unstructured":"Bhadada SK et al (2013) Deliberate total parathyroidectomy: a potentially novel therapy for tumor-induced hypophosphatemic osteomalacia. J Clin Endocrinol Metab 98(11):4273\u20134278","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1317_CR56","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jbmr.4184","volume":"36","author":"Y Imanishi","year":"2021","unstructured":"Imanishi Y et al (2021) Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia. J Bone Miner Res 36(2):262\u2013270","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1317_CR57","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","volume":"36","author":"SM Jan de Beur","year":"2021","unstructured":"Jan de Beur SM et al (2021) Burosumab for the treatment of tumor-induced osteomalacia. J Bone Miner Res 36(4):627\u2013635","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1317_CR58","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/jbmr.4280","volume":"36","author":"MP Whyte","year":"2021","unstructured":"Whyte MP (2021) Tumor-induced osteomalacia: treatment progress using burosumab, an anti-FGF23 monoclonal antibody. J Bone Miner Res 36(4):625\u2013626","journal-title":"J Bone Miner Res"},{"issue":"12","key":"1317_CR59","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/jbmr.4318","volume":"36","author":"IR Hartley","year":"2021","unstructured":"Hartley IR, Collins MT (2021) Burosumab for tumor-induced osteomalacia: not enough of a good thing. J Bone Miner Res 36(12):2453\u20132454","journal-title":"J Bone Miner Res"},{"issue":"11","key":"1317_CR60","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jbmr.4900","volume":"38","author":"SM Jan de Beur","year":"2023","unstructured":"Jan de Beur SM et al (2023) Burosumab improves patient-reported outcomes in adults with tumor-induced osteomalacia: mixed-methods analysis. J Bone Miner Res 38(11):1654\u20131664","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1317_CR61","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00198-022-06516-6","volume":"34","author":"C Crotti","year":"2023","unstructured":"Crotti C et al (2023) Long-term use of burosumab for the treatment of tumor-induced osteomalacia. Osteoporos Int 34(1):201\u2013206","journal-title":"Osteoporos Int"},{"key":"1317_CR62","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-22-0317","author":"L Aliberti","year":"2023","unstructured":"Aliberti L et al (2023) Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment. Endocrinol Diabetes Metab Case Rep. https:\/\/doi.org\/10.1530\/EDM-22-0317","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"11","key":"1317_CR63","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1515\/cclm-2020-0460","volume":"58","author":"ML Piketty","year":"2020","unstructured":"Piketty ML et al (2020) FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference. Clin Chem Lab Med 58(11):e267\u2013e269","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"1317_CR64","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/jcph.570","volume":"56","author":"X Zhang","year":"2016","unstructured":"Zhang X et al (2016) Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J Clin Pharmacol 56(2):176\u2013185","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"1317_CR65","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/jbmr.3162","volume":"32","author":"D Ovejero","year":"2017","unstructured":"Ovejero D et al (2017) Octreotide is ineffective in treating tumor-induced osteomalacia: results of a short-term therapy. J Bone Miner Res 32(8):1667\u20131671","journal-title":"J Bone Miner Res"},{"issue":"11","key":"1317_CR66","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/modpathol.2016.137","volume":"29","author":"JC Lee","year":"2016","unstructured":"Lee JC et al (2016) Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol 29(11):1335\u20131346","journal-title":"Mod Pathol"},{"issue":"14","key":"1317_CR67","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMc2020399","volume":"383","author":"IR Hartley","year":"2020","unstructured":"Hartley IR et al (2020) Targeted FGFR blockade for the treatment of tumor-induced osteomalacia. N Engl J Med 383(14):1387\u20131389","journal-title":"N Engl J Med"},{"issue":"8","key":"1317_CR68","doi-asserted-by":"crossref","first-page":"e10661","DOI":"10.1002\/jbm4.10661","volume":"6","author":"IR Hartley","year":"2022","unstructured":"Hartley IR et al (2022) Infigratinib reduces fibroblast growth factor 23 (FGF23) and increases blood phosphate in tumor-induced osteomalacia. JBMR Plus 6(8):e10661","journal-title":"JBMR Plus"},{"issue":"4","key":"1317_CR69","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ophtha.2020.08.026","volume":"128","author":"MT Magone","year":"2021","unstructured":"Magone MT et al (2021) Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor. Ophthalmology 128(4):624\u2013626","journal-title":"Ophthalmology"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01317-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-024-01317-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-024-01317-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T13:22:05Z","timestamp":1766755325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-024-01317-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,4]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1317"],"URL":"https:\/\/doi.org\/10.1007\/s00223-024-01317-x","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,4]]},"assertion":[{"value":"1 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The NIDCR receives research funding from Ultragenyx. The NIDCR has received past research funding from QED Therapeutics. IR was an unpaid advisory board member for Kyowa Kirin International in 2022 and KR has no further disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"24"}}